Physician profile
Tamara Cheater
NPI 1760869382
$4,932.57
in general payments reported to CMS, 2019-2025
17 companies · $2,654 in 2025
The $2,654 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $216 · 2022: $444 · 2023: $496 · 2024: $1,123 · 2025: $2,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,401 · Consulting Fee: $800 · Education: $71.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,400.98 |
| Consulting Fee | $800.00 |
| Education | $71.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,100.71 | 2022-2025 | |
| Amgen INC. | $493.47 | 2023-2025 | Otezla, Otezla, Enbrel |
| Regeneron Healthcare Solutions, INC. | $430.80 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $387.82 | 2021-2025 | Tremfya |
| Ucb, INC. | $319.67 | 2022-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $309.63 | 2021-2025 | |
| Genzyme Corporation | $214.65 | 2023-2025 | |
| Leo Pharma INC. | $166.22 | 2021-2023 | Adbry |
| Lilly USA, LLC | $119.49 | 2022-2025 | Ebglyss, Olumiant, Taltz |
| Mayne Pharma Commercial LLC | $109.42 | 2021-2022 | |
| Galderma Laboratories, L.P. | $77.86 | 2021-2025 | Aklief |
| Pfizer INC. | $52.29 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $43.44 | 2025 | Zoryve |
| Almirall LLC | $38.53 | 2022 | |
| Blueprint Medicines Corporation | $30.51 | 2025 | Ayvakit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $24.57 | 2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $13.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Cheater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.